SuperworthZoetis ZTS
- Market cap
- $33.5B
- PE
- 13.3×
- 10y median 37.7×
- Forward PE
- 13.1×
- 10y median 30.5×
- Price to sales
- 3.5×
- EV/EBIT
- 11.6×
- Revenue, 12 months
- $9.5B
- +1% on a year ago
- Net margin
- 27.5%
- Free cash flow yield
- 7.1%
Zoetis trades at 13.3× trailing earnings, cheaper than 96% of the last ten years. Revenue was $9.5B over the last twelve months, up 1% on a year earlier with a 27% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.2B+7% | $2.2B+9% | $2.2B+10% | $2.4B+8% | $2.4B+11% | $2.3B+5% | $2.2B+0% | $2.5B+5% | $2.4B+1% | $2.4B+3% | $2.3B+3% | $2.5B−0% | |
| Cost of revenue | $638M+5% | $728M+12% | $643M+9% | $668M+10% | $701M+10% | $707M−3% | $618M−4% | $664M−1% | $683M−3% | $712M+1% | $641M+4% | $673M+1% |
| Gross profit | $1.5B+9% | $1.5B+7% | $1.5B+10% | $1.7B+8% | $1.7B+12% | $1.6B+8% | $1.6B+2% | $1.8B+7% | $1.7B+2% | $1.7B+4% | $1.6B+3% | $1.8B−1% |
| R&D | $152M+13% | $174M+18% | $162M+14% | $171M+17% | $167M+10% | $186M+7% | $162M+0% | $166M−3% | $170M+2% | $199M+7% | $180M+11% | $173M+4% |
| SG&A | $525M+5% | $565M+10% | $547M+8% | $581M+5% | $565M+8% | $625M+11% | $574M+5% | $614M+6% | $579M+3% | $619M−1% | $588M+2% | $592M−4% |
| $782M+9% | $701M+2% | $797M+13% | $864M+5% | $915M+17% | $763M+9% | $812M+2% | $967M+12% | $932M+2% | $809M+6% | $800M−2% | $922M−5% | |
| Interest expense | $59M+11% | $59M−5% | $58M−8% | $59M+2% | $57M−3% | $51M−14% | $54M−7% | $53M−10% | $58M+2% | $57M+12% | $62M+15% | $61M+15% |
| Pre-tax income | $717M+8% | $650M+10% | $747M+7% | $780M−11% | $874M+22% | $732M+13% | $773M+4% | $912M+17% | $887M+2% | $761M+4% | $758M−2% | $866M−5% |
| $121M−13% | $127M−4% | $148M+1% | $156M−23% | $182M+50% | $151M+19% | $171M+16% | $186M+19% | $166M−9% | $158M+5% | $157M−8% | $175M−6% | |
| Net income | $596M+13% | $525M+14% | $599M+9% | $624M−7% | $682M+14% | $581M+11% | $602M+1% | $726M+16% | $721M+6% | $603M+4% | $601M−0% | $691M−5% |
| $1.29+14% | $1.14+15% | $1.31+10% | $1.37−6% | $1.50+16% | $1.29+13% | $1.34+2% | $1.63+19% | $1.63+9% | $1.37+6% | $1.42+6% | $1.65+1% | |
| 461.4M−2% | 460.1M−1% | 458.8M−1% | 456M−2% | 453.5M−2% | 451.1M−2% | 448M−2% | 445.5M−2% | 443.2M−2% | 438.6M−3% | 422.4M−6% | 417.7M−6% |
Gross profit: 58 periods, Q1 FY12 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: 58 periods, Q1 FY12 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY12: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 13 periods, Q4 FY13 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $2.3B | $2.2B to $2.4B | $1.51 | $1.46 to $1.56 | 10 |
| Q4 FY26 | $2.2B | $2.2B to $2.3B | $1.30 | $1.24 to $1.34 | 10 |
| Q1 FY27 | $2.3B | $2.2B to $2.3B | $1.52 | $1.47 to $1.59 | 8 |
| Q2 FY27 | $2.5B | $2.4B to $2.5B | $1.86 | $1.80 to $1.94 | 8 |
| Q3 FY27 | $2.3B | $2.3B to $2.4B | $1.57 | $1.52 to $1.64 | 8 |
| Q4 FY27 | $2.3B | $2.2B to $2.4B | $1.38 | $1.34 to $1.44 | 8 |
| Q1 FY28 | $2.3B | $2.2B to $2.4B | $1.58 | $1.53 to $1.65 | 9 |
| Q2 FY28 | $2.5B | $2.5B to $2.6B | $1.98 | $1.92 to $2.07 | 9 |
Peers
Companies in Healthcare nearest Zoetis' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ZTSZoetis | $33.5B | 13.3× | 37.7× | 13.1× | 3.5× | +1% | 27.5% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| CNCCentene | $34.7B | n/m | 20.7× | 15.0× | 0.2× | +14% | −2.5% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| RMDResMed | $36.5B | 24.2× | 37.3× | 20.8× | 6.5× | +10% | 26.9% |
| RPRXRoyalty Pharma | $36.7B | 36.3× | 20.4× | 12.9× | 14.5× | +10% | 32.1% |
| BIIBBiogen | $37B | 44.4× | 16.1× | 19.1× | 3.7× | +0% | 8.3% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| WSTWest Pharmaceutical Services | $27.6B | 50.2× | 45.8× | 42.2× | 8.3× | +12% | 17.0% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| Peer median | $34.1B | 37.6× | 36.9× | 23.7× | 6.3× | +10% | 17.7% |
Investors who own it
Investors we follow who held Zoetis at the end of Jun 30, 2026, from their 13F filings.
- Ruane, Cunniff & GoldfarbRuane, Cunniff & Goldfarb (Sequoia Fund)2.6% of portfoliotrimmed
- Polen CapitalPolen Capital0.2% of portfoliotrimmed
- Tom GaynerMarkel Group0.0% of portfolionew
- Baillie GiffordBaillie Gifford0.0% of portfoliotrimmed
More on Zoetis
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 92Healthcare stocks cheapest against their own PE history
- #5of 33Healthcare stocks with the highest dividend yields
- #8of 51Healthcare stocks with the lowest forward PE
Its groups
About
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .